ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025

Core Insights - ProKidney Corp. will present two posters at the American Society of Nephrology's Kidney Week from November 6-9, 2025, including a late-breaking poster on the Phase 2 REGEN-007 study results [1][2] Group 1: Presentation Details - The late-breaking poster is titled "Renal Autologous Cell Therapy in Diabetes and CKD (Phase 2 REGEN-007 Study Results)" and will be presented on November 6, 2025, from 10:00 AM to 12:00 PM CST [2] - The other poster presentation is focused on "Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel," also scheduled for November 6, 2025, during the same time frame [2] Group 2: Company Background - ProKidney Corp. specializes in cellular therapeutics for chronic kidney disease (CKD) and was founded in 2015 after a decade of research [3] - The company's lead product candidate, rilparencel (REACT), is a patented autologous cellular therapy currently in the Phase 3 REGEN-006 (PROACT 1) study, aimed at preserving kidney function in patients with advanced CKD and type 2 diabetes [3]